Table 6.
Unadjusted | Adjusted for baseline characteristics* | Adjusted for baseline characteristics and pre-AF complications† | |
30 day mortality | |||
Class I antiarrhythmic agents‡ | 0.30 (0.15 to 0.63) | 0.38 (0.18 to 0.81) | 0.42 (0.19 to 0.89) |
Sotalol | 0.21 (0.05 to 0.85) | 0.26 (0.06 to 1.12) | 0.31 (0.07 to 1.32) |
Amiodarone | 1.23 (0.81 to 1.87) | 1.21 (0.77 to 1.90) | 1.08 (0.68 to 1.74) |
Electrical cardioversion | 1.22 (0.75 to 2.01) | 1.24 (0.73 to 2.10) | 1.16 (0.66 to 2.03) |
1 year mortality | |||
Class I antiarrhythmic agents‡ | 0.41 (0.24 to 0.70) | 0.54 (0.30 to 0.95) | 0.58 (0.33 to 1.04) |
Sotalol | 0.19 (0.06 to 0.63) | 0.26 (0.08 to 0.85) | 0.31 (0.09 to 1.02) |
Amiodarone | 1.12 (0.78 to 1.63) | 1.14 (0.75 to 1.73) | 1.03 (0.67 to 1.57) |
Electrical cardioversion | 1.24 (0.81 to 1.91) | 1.33 (0.82 to 2.16) | 1.27 (0.78 to 2.09) |
*Adjusted for grouping of atrial fibrillation (AF) including paroxysmal AF, chronic AF, and no previous AF; pulse rate; systolic blood pressure; age; history of myocardial infarction; angina; percutaneous transluminal coronary angioplasty; Killip class; and smoking class (previous, current, never).
†In addition to the above demographics, adjusted for significant pre-AF complications including worsening heart failure, shock, acute ventricular septal defect, and stroke.
‡Includes procainamide, quinidine, disopyramide, encainide, flecainide, and propafenone.